|
Abstract
|
Abstract
Multiple myeloma (MM) is a hematological malignancy that remains incurable because
most patients will eventually relapse or become refractory to the treatments. Novel agents
are currently in development for the treatment of relapsed/refractory MM, including
immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cell signaling
targeted therapies, and strategies targeting the tumor microenvironment. for this purpose
the conformational structure of the hexapeptide H3N+-FDDARL-COO-, H3N+-FVDVRLCOO-,
H3N+-FSDARL-COO- has been investigated by the PCILO method. The
computational results show this tree structure have no functionality group for bind to M
protein. Moreover, H3N+-FVDVRL-COO- has assumes the somewhat amphipathic
structure.
|